Aposcience AG   Report issue

For profit Phase 2
Founded: Vienna Austria (2008)

Organization Overview

First Clinical Trial
2020
NCT04277598
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Aposcience AG

Active Ingredients

Drugs in Phase 2 Trials (1)

lorazepam (ativan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Diabetic Foot (Phase 2)

Foot Ulcer (Phase 2)

Ulcer (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 1
  • # of Trial APIs: 1